GSK's Mekinist recommended in Europe as Novartis looks on
This article was originally published in Scrip
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended GlaxoSmithKline's Mekinist (trametinib) as a single agent treatment for melanoma with a BRAF V600 mutation. Mekinist is part of GSK's $16bn sale of its oncology division to Novartis through the mega asset swap deal announced earlier this week (scripintelligence.com, 22 April 2014).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.